Michael A. Alrutz, JD, PhD

Dr. Alrutz joined Chimerix in 2012 and was named Vice President, General Counsel in September 2014. From 2002 to 2011, Dr. Alrutz was counsel to Trimeris, Inc. (NASDAQ: TRMS), serving in a variety of in-house positions, most recently as General Counsel. While at Trimeris, Dr. Alrutz had primary responsibility and oversight of the company’s legal department during the development and commercialization of FUZEON^®, a first-in-class viral fusion inhibitor for the treatment of HIV. Dr. Alrutz received his JD from Duke University School of Law and his PhD in molecular biology from the Tufts University Sackler School of Biomedical Sciences. He received his B.A. from the University of Pennsylvania.

Categorised in:

This post was written by Michelle LaSpaluto